ALAnastasiya A. Lyalina

Anastasiya A. Lyalina

*This is an algorithmically generated author record based on publicly available information.

Anastasiya A. Lyalina has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a Two-Year Comprehensive Follow-Up of Patients with Spinal Muscular Atrophy Type I Who Received Gene Therapy with Onasemnogen Abeparvovek

    by A. L. Kurenkov, L. M. Kuzenkova, E. V. Uvakina, V. V. Chernikov, S. G. Popovich, D. A. Fisenko, B. I. Bursagova, O. V. Globa, N. V. Andreenko, L. M. Abdullaeva, et al.

    Introduction . Spinal muscular atrophy (SMA) is among the most severe inherited neuromuscular diseases. The development of pathogenetic treatment methods, including gene therapy, and their widespread clinical adoption has ushered in a new era in SMA treatment, making it possible not only to halt the progression of the disease but also to improve patients’ functional capabilities. Aim : to evaluate the efficacy of gene therapy in a real-world clinical practice with a 2-year follow-up study of patients with SMA type I who received treatment with onasemnogene abeparvovec. Materials and methods . The study included 73 patients with SMA type I. The disease was confirmed by molecular genetic testing.The diagnosis of SMA type I in 22 patients (30.1%) was established due to the development of the clinical picture of the disease and after confirmatory DNA diagnostics. In 51 patients (69.9%), initially identified as part of expanded neonatal screening, the diagnosis was established immediately after the onset of the first SMA symptoms. The mean age at the time of gene therapy was 2.78±1.87 months (95% CI 2.35–3.22), min 1.00, max 7.00. A comprehensive assessment of treatment effectiveness included clinical (the main the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores) and electroneuromyographic (latency, amplitude and area of the negative peak of the distal compound muscle action potential during electrical stimulation of the ulnar nerve at the wrist, the motor nerve conduction velocity of the ulnar nerve on the forearm) parameters before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results . Following gene therapy, a large number of patients with SMA type I were able to achieve basic motor skills: 42.5% had good head control in the prone position; 78.1% rolled over from a supine to prone position; 47.2% sitting without support; 31.9% standing with assistance; 23.2% hands-&-knees crawling; 20.0% walking with assistance; 13.2% standing alone; 5.7% walking alone. However, most patients reached motor development milestones later than the WHO standards. By the end of the observation period, the HINE-2 score in patients with SMA type I significantly increased and amounted to Me 18.50 (16.00–24.00) points, with three children achieving the maximum score. The CHOP-INTEND scale score also increased significantly and amounted to Me 60.00 (58.00–64.00) points by the end of the 2-year observation period, with 17 children (23.3%) achieving the maximum score. Before gene therapy, patients with type I SMA had low values of the amplitude [Me 0.32 mV (0.15–0.81)] and area [Me 0.80 ms×mV (0.36–1.70)] of the compound muscle action potential. 24 months after gene therapy, the values of the amplitude and area significantly increased [Me 0.80 mV (0.60–1.20) and Me 1.40 ms×mV (1.00–2.10), respectively]. However, they did not reach the electroneuromyographic values of children without neurological pathology. During clinical and electroneuromyographic assessment in the dynamics of 2-year follow-up, it was not possible to establish statistically significant differences in patients with SMA type I depending on the onset of expanded neonatal screening. Conclusion . Gene therapy in patients with SMA type I results in significant improvements in motor development. Despite persistent delays in motor skill development, a large number of patients achieved key milestones in early motor development, as demonstrated by significant increases in HINE-2 and CHOP-INTEND scores and improved electroneuromyographic parameters.

  • Open Access

    Intrafamilial Polymorphism of Clinical Symptoms in Patients with Niemann-Pick Disease Type A

    by A. A. Rusakova, N. N. Mazanova, A. A. Pushkov, G. B. Movsisyan, D. S. Demianov, I. S. Zhanin, A. A. Lyalina, T. A. Bokova, A. A. Chulkova, K. V. Savostyanov

    Introduction . Niemann-Pick disease type A (NPD type A) is the most severe form of acid sphingomyelinase deficiency, a rare inherited disorder of the lysosomal storage disorders with autosomal recessive inheritance caused by biallelic pathogenic variants in the SMPD1 gene. Since 2023, enzyme replacement therapy with olipudase alfa has been used to treat patients with NPD in Russia. This therapy does not alter the prognosis for neurological forms of the disease, as it does not penetrate the blood-brain barrier. Therefore, the only effective treatment, along with symptomatic therapy, for the systemic manifestations of NPD type A is hematopoietic stem cell transplantation, which does not prevent central nervous system damage. Early laboratory diagnostics using biochemical and molecular genetic diagnostic methods are crucial for timely diagnosis and treatment of patients with this form of the disease. Aim : to describe intrafamilial polymorphism of clinical symptoms of NPD, type A using the example of two siblings from the same family. Materials and methods . Clinical observation and diagnostics were conducted at the National Medical Research Center for Children’s Health of the Russian Ministry of Health from 2012 to 2026 in a single family in which the first proband with clinical symptoms characteristic of NBP type A was identified in 2012. Acid sphingomyelinase activity was measured in dried blood spots using tandem mass spectrometry, and nucleotide variants in the SMPD1 gene were identified using Sanger sequencing. Familial segregation analysis was performed for the proband and eight family members. Results . Diagnosis of the first proband revealed a significant decrease in acid sphingomyelinase activity in the patient’s spinal cord. Sequencing revealed the presence of two pathogenic heterozygous variants in the SMPD1 gene: c.996del ( p.Phe333Serfs52 ) and c.1252C > T ( p.Arg418 ). Carriage of the pathogenic causative variants in the SMPD1 gene was confirmed in the parents. The second proband was diagnosed on the second day of life. As a result of the timely diagnosis, immunotherapy (bone marrow transplant) was prescribed, which determined the child’s prognosis. Conclusion . Using two siblings from the same family as an example, polymorphism in the clinical symptoms of NPD type A was demonstrated. Early diagnosis of this form of the disease significantly improves the prognosis and enables timely initiation of therapy.

  • Open Access

    Results of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease

    by Людмила Михайловна Кузенкова, Алексей Львович Куренков, Евгения Владимировна Увакина, Дарья Андреевна Фисенко, Владислав Владимирович Черников, Елена Леонидовна Семикина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Оксана Валерьевна Глоба, Наталья Владимировна Андреенко, et al.

    Introduction. The use of gene therapy in patients with spinal muscular atrophy (SMA) has led to a significant improvement in the prognosis of motor development. The inclusion of SMA in the expanded neonatal screening in the Russian Federation allowed not only identifying patients as early as possible, but also gene therapy at the presymptomatic stage of the disease became available for some of them.Objective. To evaluate the effectiveness of gene therapy in real clinical practice during 2 years of follow-up of SMA patients treated with onasemnogen abeparvovec at the presymptomatic stage of the disease.Materials and methods. The study included thirty five SMA children, with a genetically verified diagnosis of SMA without developing symptoms of the disease. The diagnosis of SMA was established during the pilot project of the extended neonatal screening or from 01/01/2023 as part of the extended neonatal screening. The diagnosis was verified during DNA diagnostics. Deletion of exons 7 and/or 8 of the SMN1 gene in the homozygous state was detected in all children. All patients received gene therapy with onasemnogen abeparvovec, the average age at the time of therapy was 2.00 ± 0.94 months (95% CI 1.68–2.32), min — 1.00, max — 5.00. A comprehensive assessment was conducted of clinical (the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores), electroneuromyographic (latency, amplitude and area of the negative peak of the compound muscle action potential during electrical stimulation of the ulnar nerve on the wrist; the motor nerve conduction velocity of the ulnar nerve on the forearm) and biochemical parameters (levels of light and heavy chains of neurofilaments (NF) in blood serum in SMA patients at the presymptomatic stage before initiation of gene therapy and after 6, 12, 18, and 24 months after its implementation.Results. In our study, SMA patients at the presymptomatic stage, both before and after gene therapy, had motor development in accordance with age norms and did not significantly differ from children without neurological pathology. A comparative analysis of the electroneuromyographic parameters in SMA children and a group of healthy children revealed no statistically significant differences in patients at the presymptomatic stage of SMA on the background of gene therapy. A comparative analysis of the levels of light and heavy NF chains in the blood serum in SMA patients at the presymptomatic stage before gene therapy and 76 neurologically healthy children obtained in a recent study showed the level of light NF chains in SMA to be significantly higher (p < 0.001) — Me — 6.00, Q1; Q3 = 6.00; 31.43 pg/ml and Me — 4.00, Q1; Q3 = 2.50; 9.57 pg/ml, respectively. At the same time, the level of heavy NF chains did not significantly differ when comparing SMA patients at the presymptomatic stage before gene therapy with healthy peers. The use of onasemnogen abeparvovec in SMA patients at the presymptomatic stage led to a statistically significant decrease in the level of light chains NF in the blood serum. The maximum decrease in NF was observed 3–6 months after the gene therapy.Conclusion. Carrying out gene therapy using the onasemnogen abeparvovek in SMA patients at the presymptomatic stage made it possible to prevent the development of symptoms of the disease and achieve the main stages of motor development milestones according to WHO criteria.Compliance with ethical standards. Permission to conduct this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health (Minutes of the Local ethics committee, meeting No. 10 dated 10/06/2022).Contribution:Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A. — concept and design of research, writing, editing;Chernikov V.V. — statistical data processing, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: November 6, 2024Accepted: December 1, 2024Published: January 31, 2025


  • Open Access

    Filamin A (FLNA) gene mutation-associated disease: results of a multicenter study

    by Владимир Петрович Мирошниченко, Dmitry Yu. Ovsyannikov, Mikhail A. Abramyan, Людмила Михайловна Кузенкова, Victoria A. Aisyna, Evgenia V. Boytsova, Шамиль Абдулвахидович Гитинов, Ольга Викторовна Гнеушева, Александр Валерьевич Горбунов, Валерий Викторович Горев, et al.

    Introduction. Pathogenic variants of the FLNA gene cause damage to various organs and systems formed in the embryonic period. The most frequently affected organs are the brain (epilepsy), cardiovascular system (congenital heart defects, pulmonary hypertension — PH), and lungs (emphysema). The aim of the study: genetic, clinical, laboratory, and instrumental characteristics of patients with a disease caused by pathogenic variants of the FLNA gene. Materials and methods. Six girls with identified pathogenic variants of the FLNA gene were observed. The methods used: genealogical, whole exome sequencing, Sanger sequencing, electroencephalography, brain MRI, echocardiography, right heart catheterization with determination of pressure and resistance in the pulmonary circulation and pulmonary capillary wedge pressure, CT of the chest organs. Results. The article presents the results of a molecular genetic study of the FLNA gene. All patients were diagnosed with periventricular nodular heterotopia and psychomotor retardation, 2 of them had epilepsy; 4 children had heart valve dysplasia; 3 had patent ductus arteriosus, 3 had septal defects, 2 had bicuspid aortic valve, 5 had pulmonary hypertension; 5 had pulmonary emphysema; 1 had congenital diaphragmatic hernia. Two patients died during the observation period. Conclusion. Diagnosis and observation of patients with pathogenic variants of the FLNA gene is a challenge for a multidisciplinary team of doctors at a multidisciplinary pediatric hospital. The presented cohort of 6 patients reflects the most typical manifestations of this pathology, the severity and rate of development of disease in infants.


  • Open Access

    Clinical case of a patient with AADC deficiency of L-aromatic amino acid decarboxylase: diagnostic route and therapeutic options

    by Евгения Владимировна Увакина, Людмила Михайловна Кузенкова, Dmitry I. Gukosyan, София Георгиевна Попович, Татьяна Владимировна Подклетнова, Anastasia A. Lyalina, Александр Алексеевич Пушков, Kirill V. Savostyanov, Yulia A. Kurova, Дарья Сергеевна Николенко, et al.

    L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disease characterized by impaired biosynthesis of neurotransmitters and manifested by disorders of movement and autonomic regulation. In the article there is discussed the diagnostic path and treatment options for a 7-year patient with severe AADC deficiency. Combination of severe neurological disorders (muscular hypotension, dystonia, hyperkinesis, oculogyric crises) and autonomic disorders (increased sweating, hypersalivation, thermoregulation disorders, nasal congestion, dyspepsia, etc.) is clearly demonstrated to require the detection of 3-O-methyldopa in dried blood spots to exclude AADC deficiency. Given the emergence of gene therapy, which is available to patients with a confirmed diagnosis of AADC deficiency in Russia within the criteria of the Circle of Kindness Foundation, it is necessary to popularize information about L-aromatic amino acid decarboxylase deficiency in the general medical community, to improve the prognosis and quality of life in AADC patients.


  • Open Access

    Delayed motor, mental and speech development and congenital brain malformations: the first description of Zhu–Tokita–Takenouchi–Kim syndrome in Russia

    by O. B. Kondakova, A. P. Gudkova, S. V. Demyanov, Yu. I. Davydova, A. A. Lyalina, D. I. Grebenkin, E. A. Bakovich, I. V. Kanivets, D. S. Demyanov, I. S. Zhanin, et al.

    Zhu–Tokita–Takenouchi–Kim syndrome (ZTTK syndrome) is a rare autosomal dominant nuclear speckleopathy characterized by developmental delay, hypotonia, intellectual disability, facial dysmorphism in association with variable brain malformations, musculoskeletal abnormalities and ocular involvement. Currently, 87 cases of ZTTK syndrome have been described worldwide. The syndrome caused by mutations in the SON gene, located on the long arm of chromosome 21 (21q22.11). Nonsense and frameshift mutations have been described in the SON gene. Missense mutations, partial or whole gene deletions are less common.The aim of the work is to analyze the clinical picture and molecular genetic results of patients with confirmed ZTTK syndrome and compare them with data from foreign literature.We observed the one boy and two girls with ZTTK syndrome aged 13 months to 59 months, averaging about 38 months. DNA diagnostic was performed by next generation sequencing. All patients and all parents were confirmed by Sanger sequening. Three pathogenic variants were identified: c.5753_5756delTTAG (p.Val1918Glufs*87), c.1531del (p.Thr511Glnfs*9) and c.403delG (p.Glu135Asnfs*14). The first one was is most common, the other two are novel variants. Most patients had growth, motor and speech delay, seizures, hypotonia, congenital heart defects, urinary tract abnormalities and brain malformations. Comparative analysis of facial features in patients with ZTTK syndrome showed downslanting palpebral fissures, epicantal folds, broad or depressed nasal bridge, flared nares, smooth philtrum, thin upper lip and low set, rotated ears. The use of next generation sequencing as a first‑line test for research and diagnostic of ZTTK syndrome is advisable due to the pronounced clinical polymorphism.


  • Open Access

    The first description of a rare monogenic disease with polymicrogyria caused by a pathogenic variant in the gene WASF1 in monozygotic twins

    by Ольга Борисовна Кондакова, Анастасия Павловна Гудкова, Дмитрий Игоревич Гребенкин, Semen V. Demyanov, Iuliia I. Davydova, Anastasia A. Lyalina, Ilya V. Kanivets, Илья Сергеевич Жанин, Александр Алексеевич Пушков, Kirill V. Savostyanov, et al.

    Neurodevelopmental disorder without speech and variable seizures (NEDALVS) is a rare autosomal dominant inherited disorder, characterized by motor development delay, mental retardation, wide-based gait, autism spectrum disorders and seizures. Currently, fifteen cases of NEDALVS have been described worldwide. NEDALVS caused by mutations in the WASF1 gene, located on the long arm of chromosome 6. Nonsense-, missense-, frameshift mutations and large deletion have been described in WASF1 gene. We present the clinical case of 9-year monozygotic NEDALVS twins, accompanied by cerebral pachygyria/polymicrogyria. DNA diagnostic was performed using full genome sequencing, followed by validation using Sanger sequencing. A previously described heterozygous pathogenic variant c.1516C>T (p.R506*) in the WASF1 gene was identified. We performed the results of a comparative analysis based on the literature and our patients. All patients had delayed motor and psycho-speech development, severe mental retardation was in 53% of cases, lack of speech — 18%, autistic manifestations and seizures — 41%, wide-based gait — 29%, strabismus and feeding problems — 35%. Conclusion. WASF1 gene mutations caused a rare form of mental retardation in children. We present the first case of NEDALVS in Russian Federation and the world’s first description of pachygyria in patients, caused by WASF1 gene mutations. The use of NGS as a first-line test for research and diagnostic of neurodevelopmental disorder is determined by their non-specific clinical features.

  • Open Access

    Juvenile amyotrophic lateral sclerosis caused by a mutation in the SPTLC2 gene: case presentation

    by Луизат Муслимовна Абдуллаева, Алексей Л. Куренков, Lyudmila M. Kuzenkova, Anastasiya A. Lyalina, Victoria A. Ioksha

    Juvenile amyotrophic lateral sclerosis (ALS) is a rare group of motor neuron diseases, with the age of onset up to 25 years. Juvenile ALS more commonly has genetic origin vs. sporadic forms of ALS that develop in adulthood. Genetic analysis of these cases with early onset makes it possible to identify the genes responsible for the disease. Here we present a case of a rare variant of juvenile ALS caused due to the SPTLC2 gene mutation. Cases with early disease onset are characterized by slow progression and variable phenotype, which often makes accurate diagnosis challenging. Therefore patients with combined upper and lower motor neuron disorders aged under 25 years should undergo comprehensive examination, in particular to identify gene mutations.

  • Open Access

    The debut and course of the neonatal form of propionic aciduria: a clinical case

    by Ангелина Викторовна Соколова, Tatiana V. Bushueva, Lyudmila M. Kuzenkova, Tatyana Е. Borovik, Oksana V. Globa, Tatyana V. Podkletnova, Anastasiya A. Lyalina, Alexander A. Pushkov, Nataliya N. Mazanova, Ekaterina Yu. Zakharovа, et al.

    Propionic aciduria (PA) is an autosomal recessive hereditary disease from the group of organic aciduria, caused by a deficiency of propionyl-CoA carboxylase, leading to impaired metabolism of methionine, threonine, valine, isoleucine, and fatty acids with an odd number of carbon atoms and cholesterol. The neonatal form of PA manifests itself during the first week of life, is characterized by an acute onset and a crisis course, which is accompanied by severe metabolic acidosis, hypoglycemia, hyperketonemia, hyperammonemia. Clinical symptoms are dominated by neurological disorders up to stupor or coma, which can lead to death. Since 2023, expanded neonatal screening has been introduced throughout the Russian Federation, which includes 36 groups of nosologies, as well as a number of hereditary metabolic diseases. Despite the inclusion of this pathology in expanded neonatal screening, doctors’ awareness of clinical manifestations and necessary therapy remains insufficient. Often such patients are diagnosed with, for example: hypoxic-ischemic damage to the central nervous system, acute meningoencephalitis, and others, which leads to inadequate therapy with the development of fatal neurological consequences. Therefore, the totality of knowledge and alertness of doctors regarding diseases from the group of hereditary metabolic diseases will help not only to suspect this pathology in a timely manner, but also to prescribe adequate therapy in time, which in the future will make it possible to prevent serious consequences and neurological disorders, as well as disability of patients.

  • Open Access

    Prospects of etiopathogenetic treatment of Huntington’s disease

    by O. B. Kondakova, S. V. Demyanov, A. V. Krasivskaya, G. V. Demyanov, D. I. Grebenkin, Yu. I. Davydova, A. A. Lyalina, E. R. Radkevich, K. V. Savostyanov

    Huntington’s disease is a serious inherited neurodegenerative disorder characterized by of motor, cognitive and psychiatric features. The disease is caused by an abnormally expanded CAG repeat expansion in the HTT gene and the production of mutant huntingtin protein.The disease usually manifests in adulthood, but the manifestation in childhood and youth is also described, which is noted in 5–10 % of cases. The disease predominantly affects the neostriatum, resulting in a characteristic clinical picture.The most promising approaches to etiotropic therapy of Huntington’s disease are a number of DNA- (CRISPR/Cas9 system) and RNA-directed methods (antisense oligonucleotides, RNA interference), methods that directly reduce the level of mutant gentingtin (chimera molecules), as well as approaches based on inactivating the DNA mismatch repair system using the FAN1 enzyme.